These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23920413)

  • 1. Ehlers-Danlos syndrome: a showcase of conditions that lead to understanding matrix biology.
    Byers PH; Murray ML
    Matrix Biol; 2014 Jan; 33():10-5. PubMed ID: 23920413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The Ehlers-Danlos syndrome: the extracellular matrix scaffold in question].
    Fichard A; Chanut-Delalande H; Ruggiero F
    Med Sci (Paris); 2003 Apr; 19(4):443-52. PubMed ID: 12836217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Ehlers-Danlos syndromes, rare types.
    Brady AF; Demirdas S; Fournel-Gigleux S; Ghali N; Giunta C; Kapferer-Seebacher I; Kosho T; Mendoza-Londono R; Pope MF; Rohrbach M; Van Damme T; Vandersteen A; van Mourik C; Voermans N; Zschocke J; Malfait F
    Am J Med Genet C Semin Med Genet; 2017 Mar; 175(1):70-115. PubMed ID: 28306225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ehlers-Danlos Syndromes, Joint Hypermobility and Hypermobility Spectrum Disorders.
    Micale L; Fusco C; Castori M
    Adv Exp Med Biol; 2021; 1348():207-233. PubMed ID: 34807421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Ehlers-Danlos syndrome, a disorder with many faces.
    De Paepe A; Malfait F
    Clin Genet; 2012 Jul; 82(1):1-11. PubMed ID: 22353005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A recessive form of the Ehlers-Danlos syndrome caused by tenascin-X deficiency.
    Schalkwijk J; Zweers MC; Steijlen PM; Dean WB; Taylor G; van Vlijmen IM; van Haren B; Miller WL; Bristow J
    N Engl J Med; 2001 Oct; 345(16):1167-75. PubMed ID: 11642233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Ehlers-Danlos syndromes.
    Yeowell HN; Pinnell SR
    Semin Dermatol; 1993 Sep; 12(3):229-40. PubMed ID: 8217561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Vascular Ehlers-Danlos syndromes--biochemical and molecular-genetic investigations].
    Lund AM
    Ugeskr Laeger; 2006 Feb; 168(9):915-20. PubMed ID: 16513057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions of human tenascin-X domains with dermal extracellular matrix molecules.
    Egging D; van den Berkmortel F; Taylor G; Bristow J; Schalkwijk J
    Arch Dermatol Res; 2007 Jan; 298(8):389-96. PubMed ID: 17033827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deficiency of the core proteins of dermatan sulphate proteoglycans in a variant form of Ehlers-Danlos syndrome.
    Fushimi H; Kameyama M; Shinkai H
    J Intern Med; 1989 Dec; 226(6):409-16. PubMed ID: 2562251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ehlers-Danlos syndrome: classifications, oral manifestations, and dental considerations.
    Abel MD; Carrasco LR
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Nov; 102(5):582-90. PubMed ID: 17052632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular aspects of the Ehlers-Danlos Syndromes.
    Malfait F
    Matrix Biol; 2018 Oct; 71-72():380-395. PubMed ID: 29709596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ehlers-Danlos syndromes and Marfan syndrome.
    Callewaert B; Malfait F; Loeys B; De Paepe A
    Best Pract Res Clin Rheumatol; 2008 Mar; 22(1):165-89. PubMed ID: 18328988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical alterations of uterine leiomyoma extracellular matrix in type IV Ehlers-Danlos syndrome.
    Wegrowski Y; Bellon G; Quéreux C; Maquart FX
    Am J Obstet Gynecol; 1999 Apr; 180(4):1032-4. PubMed ID: 10203676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Collagen type I, III, IV and V and fibronectin in skin biopsies of patients with Ehlers-Danlos syndrome and cutis laxa].
    Shekhonin BV; Semiachkina AN; Makkaev KhM; Domogatskiĭ SP; Idel'son GL
    Arkh Patol; 1988; 50(12):41-8. PubMed ID: 3074749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COL5A1 signal peptide mutations interfere with protein secretion and cause classic Ehlers-Danlos syndrome.
    Symoens S; Malfait F; Renard M; André J; Hausser I; Loeys B; Coucke P; De Paepe A
    Hum Mutat; 2009 Feb; 30(2):E395-403. PubMed ID: 18972565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dermal fibroblast-to-myofibroblast transition sustained by αvß3 integrin-ILK-Snail1/Slug signaling is a common feature for hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders.
    Zoppi N; Chiarelli N; Binetti S; Ritelli M; Colombi M
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt A):1010-1023. PubMed ID: 29309923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elastic fiber abnormalities in hypermobility type Ehlers-Danlos syndrome patients with tenascin-X mutations.
    Zweers MC; Dean WB; van Kuppevelt TH; Bristow J; Schalkwijk J
    Clin Genet; 2005 Apr; 67(4):330-4. PubMed ID: 15733269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ehlers-Danlos syndromes].
    Germain DP
    Ann Dermatol Venereol; 2017 Dec; 144(12):744-758. PubMed ID: 29032848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations of the alpha2(V) chain of type V collagen impair matrix assembly and produce ehlers-danlos syndrome type I.
    Michalickova K; Susic M; Willing MC; Wenstrup RJ; Cole WG
    Hum Mol Genet; 1998 Feb; 7(2):249-55. PubMed ID: 9425231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.